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Abstract
Bachground:  Activating  BRAF  mutations are present in approximately 50% of melanomas.
Although different downstream target genes of the most common mutant V600E have been
identified, the contribution of activating BRAF mutations to malignant transformation needs further
clarification.
Methods: Microarray gene analysis was performed for human melanoma cell lines harboring
BRAFV600E mutations in comparison to cell lines without this mutation.
Results: This analysis revealed a more than two fold down-regulation of 43 and an increase of 39
gene products. BAALC (Brain and acute Leukaemia, cytoplasmatic) was most prominently regulated,
since it was up-regulated in mutated cell lines by a mean of 11.45. Real time PCR analyses with RNA
from melanoma cell lines (n = 30) confirmed the BRAF-activation dependent up-regulation of BAALC.
Conclusion: BAALC, which has been associated with cell dedifferentiation and migration, may
function as a downstream effector of activating BRAF mutations during melanomagenesis.
Background
Activating mutations of the protooncogene BRAF  have
been observed in approximately fifty percent of malignant
melanomas [1]. The V600E mutant accounting for over
ninety percent of these mutations, obviates the require-
ment for segment phosphorylation of the T599 and S602
residues which is essential for a regular activation of BRAF
[2,3]. Thus, the BRAFV600E mutation leads to a continuous
stimulation of the MAP kinase cascade which results in a
variety of cellular changes such as proliferation and dedif-
ferentiation [4]. However, the role of activating BRAF
mutations with respect to course and stage of melanoma
is still not defined. On the one hand, comparable inci-
dence of activating BRAF mutations in invasive cutaneous
melanomas and benign melanocytic nevi indicate that
BRAF mutations alone are insufficient to cause malignant
transformation [2,3]. In addition, low frequency of BRAF
mutations in radial growth phase melanomas, i.e. the
early phase of melanoma progression, suggests a correla-
tion with progression rather than initiation [5]. On the
other hand, in patients with metastatic melanoma the
presence of BRAF mutations is associated with a signifi-
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cantly poorer prognosis [6]. Moreover, introduction of
BRAFV600E in melanocytes rendered them tumorigenic in
nude mice [7], while another group demonstrated that
BRAFV600E expression in human melanocytes induced cell
senescence leading to cell cycle arrest. Hence, additional
mutations have to occur to overcome this cell cycle arrest
and make the cells tumorigenic [8]. Various genes have
been identified as possible targets of the RAS/RAF/MAP
kinase pathway. In this regard, microarray gene expression
profiling allows measuring the expression of a large
number of genes at the same time and thus providing a
method for predicting the impact of oncogenes on the
expression of possible down stream target genes. For
example, microarray analyses of transfected murine
embryonic fibroblasts with oncogene expressing adenovi-
ruses helped to identify complex genetic alterations
caused by genes such as HRAS, MYC and the E2F family
[9]. Similarly, using standard cDNA microarray chips,
gene expression signatures were reported for malignant
melanoma cell lines harboring mutations in the BRAF
gene when compared to wild type cell lines [10-12]. In
this study, we used customized microarrays to identify
additional target genes of the constitutively active MAPK
pathway. The BRAFV600E dependent expression of a newly
identified potential effector gene, BAALC (brain and acute
leukaemia, cytoplasmatic) was confirmed by real time PCR
analyses in complimentary experiments in melanoma cell
lines.
Materials and methods
Melanoma cell lines and cell culture
16 human malignant melanoma cell lines harbouring
BRAFV600E mutations as well as 9 melanoma cell lines with
activating RAS mutations and 5 human malignant
melanoma cell lines without mutations in these genomic
sections were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum (Table 1). Prior to RNA
isolation the presence or absence of the V600E mutation
was confirmed by direct sequencing PCR amplicons of
BRAF exon 15.
Gene expression analysis
Three melanoma cell lines (Mel2A, IF-6, FM88) with
BRAFV600E  mutation and three without this mutation
(M26, MV3, M19) were examined by cDNA microarray
analyses as described elsewhere [13]. In brief, total cellu-
lar RNA was isolated with the RNAeasy kit (QIAGEN,
Hilden, Germany) and a subsequent DNase digestion was
included. Hybridization probes were generated by indi-
rect labeling with Cy3 and Cy5 dyes, using the CyScribe
cDNA Post Labeling Kit RPN5660 (Amersham Bio-
sciences Europe, Freiburg, Germany). All procedures were
performed according to the manufacturer's instructions
with 60 μg of RNA. Each experiment was performed as
sandwich hybridization, i.e. instead of a cover slip a sec-
ond microarray slide was used. The 4.6 K cDNA chips
were generated by the group of M. Krause [http://
www.imt.uni-marburg.de (Research, Microarray Unit)]
and contained the GF200 set of Research Genetics cDNAs.
Fluorescence labeled cDNA was spotted in duplicates. A
flip color experiment was included. Samples were hybrid-
ized to microarrays for 16 h at 55°C. Chips were scanned
with a GMS 418 fluorescent scanner (MWG-Biotech), and
the images were analyzed with IMAGENE 3.0 software.
Quantitative RT-PCR analyses for BAALC
Relative expression of BAALC was determined by real time
PCR analyses in Sybr green technology using the compar-
ative ΔΔCT method. Total RNA was isolated from approx-
imately 3 × 106 cells of human melanoma cell lines or
from 25 six μm thick kryosections of melanoma tissue
samples. Samples of total RNA were subjected to reverse
transcription. Primers for BAALC  were designed with
Primer Express software (Applied Biosystems, Weiterstadt,
Germany) and read as following: sense 5'-AGC-CGC-
CGC-CAG-AGC-CGA-CAG-3'; antisense 5'-GG-GAT-CCA-
GTG-CCG-TGA-AGG-3'. For the evaluation of BAALC
expression the thermal cycling conditions comprised an
initial denaturation step at 95°C for 10 min, then 43
cycles of three-step PCR including 94°C for 30 sec, 60°C
for 30 sec and 72°C for 40 sec. GAPDH (Applied Biosys-
Table 1: BRAF and RAS mutational status of the analyzed cell 
lines.
Wild type BRAF/RAS1 BRAF mutated2 RAS mutated3
MV3 FM88 (V600K) MaMel79 (Q61K)5
M19 IF-6 (V600E) MaMel91 (Q61K)
MaMel24 Mel2a (V600E) MaMel28 (Q61R)
MaMel71 FM55 (V600E) MaMel26a (Q61R)
MaMel15 FM82 (V600E) M26 (Q61R)
MaMel19 (V600E) FM79 (Q61L)
MaMel83 (V600E) BLM (Q61R)
MaMel86a (V600E) MaMel5 (Q61R)








1 Respective cell lines possess neither a BRAF nor a RAS mutation
2 Listed cell lines are mutated for BRAF. The mutation is given in 
brackets.
3 Listed cell lines are mutated for RAS. The mutation is given in 
brackets.
4 the MaMel cell lines are short term biopsy-derived cell lines 
demonstrating strong concordance with the mutational status of the 
corresponding tissues [24].
5 Cell lines are hemi- or homozygote for the respective mutation.Journal of Carcinogenesis 2008, 7:1 http://www.carcinogenesis.com/content/7/1/1
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tems) served as endogenous control. The relative expres-
sion level of BAALC, normalized to GAPDH and relative
to the randomly selected human melanoma cell line
FM79 (BRAF wt/wt) was calculated as   with ΔΔCT
= (CT BAALC, sample - CT GAPDH, sample) - (CT BAALC, FM79 - CT
GAPDH, FM79). CT is defined as the cycle when the threshold
level of fluorescence is reached.
Statistical analysis
In microarray analyses, the threshold value for up or
down regulation of gene expression was defined as a more
than two fold change compared to the mean value. Data
of real time PCR studies were expressed as box-and-whisk-
ers plot. Differences between the values were evaluated by
Mann-Whitney test. p < 0.05 was considered to be signifi-
cant.
Results and Discussion
Activating mutations of RAS and BRAF result in a constant
activation of the MAP kinase pathway and eventually con-
tribute to proliferation and dedifferentiation of cancer
cells [2,14]. Although numerous target genes of the RAS/
BRAF MAP-kinase pathway have been identified so far, the
mechanism of action by which activated BRAF contributes
to the malignant transformation of melanoma cells needs
to be further elucidated. Therefore, we investigated gene
expression of human melanoma cell lines harboring acti-
vating BRAF mutations (Mel2A, IF-6, FM88) by cDNA
microarray analyses and compared their gene expression
patterns to melanoma cell lines devoid of mutations in
this genomic section (M26, MV3, M19). To this end, In
BRAFV600E  mutated cell lines a more than two fold
decrease of 43 and increase of 39 gene products was
detected (table 2). Due to the limited number of cell lines
used in the microarray experiments each candidate
revealed by this analysis should be confirmed in analysis
of larger numbers of samples. Only such confirmation
assays ascertain the respective genes to be effected by acti-
vated BRAF. Nevertheless, the most interesting gene found
by these analyses was BAALC (brain and acute leukaemia,
cytoplasmatic), since (i) it was highest up-regulated in all
three cell lines harboring BRAF mutations by an average of
11.25 fold and (ii) it was not yet described by other
groups analyzing the effect of BRAF mutation on gene
expression in melanoma [10-12,15]. The latter, i.e. find-
ing a prominent regulation of gene expression in one
study but not in others, seems at first curious. However, it
has been noticed that even when the same microarray
chips are used, different results are obtained. The use of
different expression pattern detection algorithms and lab-
dependent differences were identified as source for such
inconsistency. Lab-dependent differences include selec-
tion and treatment of samples to mRNA isolation, cDNA
probe generation, chip hybridization conditions, chip lot
and even the use of different chip scanners [16,17]. These
findings sustain the notion that confirmation assays are
mandatory in order to confirm different regulated expres-
sion for genes detected by microarray analysis.
The product of the BAALC gene has been previously dis-
cussed to be involved in cell dedifferentiation and motil-
ity. In differentiated cells BAALC  is almost exclusively
expressed in the central nervous system and in other neu-
roectodermal derived tissues. Moreover, BAALC expres-
sion has been described for CD34 positive hematopoietic
progenitor cells from the bone marrow [18]. Notably, loss
of expression of BAALC during differentiation of hemat-
opoietic progenitor cells suggests that it might function in
sustaining an undifferentiated state of these cells [19,20].
Interestingly, however, BAALC expression in both normal
and malignant astrocytes is increased upon differentia-
tion, suggesting complementary functions in different cell
types [21]. Nevertheless, it has been postulated that a
series of genes, frequently expressed in progenitor cells of
the neuroectodermal and the haematopoietic system,
maintain the proliferative capacity while inhibiting differ-
entiation [22] and BAALC may belong to this group of
genes. Recent studies performed in patients with leukae-
mic malignancies indeed suggest a role of BAALC in tum-
origenesis. For example, blast cells from 28% of patients
with acute myeloid leukaemia and 65% with acute lym-
phatic leukaemia displayed an overexpression of BAALC.
In addition, high BAALC expression was identified as an
independent risk factor in acute myeloid leukaemia [20].
The examination of 13 human tumor cell lines of non-
hematopoietic origin, however, revealed BAALC expres-
sion in only five cell lines derived from glioblastoma
while BAALC was not detectable in any of the other neo-
plastic cells indicating a specific function of BAALC in
some tumors only [18]. Furthermore, the expression of
BAALC in developing and mature muscle cells in mice
suggests a possible role of BAALC in cell locomotion or
adhesion [23].
The distinct increase of BAALC  expression in all three
BRAFV600E mutated melanoma cell lines suggests a possi-
ble function of BAALC associated with activated BRAF
mutations in melanoma and mediating cell dedifferentia-
tion and motility. As mentioned before, complementary
experiments using real time PCR analyses to measure the
relative mRNA expression of BAALC have to be performed
to confirm this correlation. To this end, BAALC expression
was determined in 16 cell lines mutated for BRAF, 5 wild
type BRAF melanoma cell lines as well as 9 melanoma cell
lines in which the MAP kinase pathway was activated by
RAS mutations. These analyses validated the first observa-
tions; BRAFV600E cell lines showed significantly (p < 0.01)
elevated mRNA levels of BAALC (Fig. 1a) when compared
to wild type cell lines. Notably, over-expression of BAALC
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Table 2: Changes of gene expression in V600E mutated melanoma cell lines compared to wild type melanoma cell lines as revealed by 
microarray gene expression profiling
Increase of gene expression Decrease of gene expression
symbol gene name fold change symbol gene name fold change
SLC2A10 solute carrier family 2 (facilitated glucose transporter), 
member 10
3,64 SELK selenoprotein K 2,14
ARG99 ARG99 protein 2,25 LPHN2 latrophilin 2 2,11
SOD3 superoxide dismutase 3, extracellular 3,71 ADRB2 adrenergic, beta-2-, receptor, surface 2,81
MAN1C1 mannosidase, alpha, class 1C, member 1 2,49 LOC51159 colon carcinoma related protein 2,56
DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 2,09 EGR2 early growth response 2 (Krox-20 homolog, 
Drosophila)
2,10
C20orf45 chromosome 20 open reading frame 45 2,70 BUB3 BUB3 budding uninhibited by benzimidazoles 3 
homolog (yeast)
2,00
RPS6KA3 ribosomal protein S6 kinase, 90 kDa, polypeptide 3 3,07 VEZATIN transmembrane protein vezatin 2,07
RGS1 regulator of G-protein signalling 1 4,62 SPIN spindlin 2,36
COL4A2 collagen, type IV, alpha 2 3,09 STS steroid sulfatase (microsomal), arylsulfatase C, 
isozyme S
2,74
ZCCHC6 zinc finger, CCHC domain containing 6 2,07 CDC2 cell division cycle 2, G1 to S and G2 to M 2,17
CNTN1 contactin 1 2,03 MT1B metallothionein 1B (functional) 2,44
MGC13105 hypothetical protein MGC13105 2,03 PITX2 paired-like homeodomain transcription factor 2 2,35
SUHW2 suppressor of hairy wing homolog 2 (Drosophila) 2,48 PRKCG protein kinase C, gamma 2,58
ICAM1 intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor
2,14 FABP5 fatty acid binding protein 5 (psoriasis-associated) 3,03
BAALC brain and acute leukemia, cytoplasmic 11,45 EPHB1 EphB1 2,13
OSBPL8 oxysterol binding protein-like 8 2,13 EGR1 early growth response 1 2,97
RAB24 RAB24, member RAS oncogene family 2,19 PIGF phosphatidylinositol glycan, class F 2,16
LOC54103 hypothetical protein LOC54103 2,16 DYRK3 dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 3
2,55
HSPC195 hypothetical protein HSPC195 2,24 RANBP6 RAN binding protein 6 2,26
EHD3 EH-domain containing 3 2,56 C10orf36 chromosome 10 open reading frame 36 2,92
CFLAR CASP8 and FADD-like apoptosis regulator 2,02 DHRS8 dehydrogenase/reductase (SDR family) member 8 2,05
ZFP28 zinc finger protein 28 homolog (mouse) 2,04 P8 p8 protein (candidate of metastasis 1) 2,08
GSTM3 glutathione S-transferase M3 (brain) 3,20 SCD4 stearoyl-CoA desaturase 4 3,23
PPP3R1 protein phosphatase 3 (formerly 2B), regulatory 
subunit B,
2,07 RAB27B RAB27B, member RAS oncogene family 3,45
APMCF1 APMCF1 protein 2,18 ZFP36L1 zinc finger protein 36, C3H type-like 1 2,22
N33 Putative prostate cancer tumor suppressor 2,05 SLC2A3 solute carrier family 2 (facilitated glucose 
transporter), member 3
2,16
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 5,29 THBS1 thrombospondin 1 2,07
NAP4 Nck, Ash and phospholipase C binding protein 2,13 FLJ90440 hypothetical protein FLJ90440 2,62
LZTS1 leucine zipper, putative tumor suppressor 1 2,00 C5orf13 chromosome 5 open reading frame 13 2,13
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 2,11 MT1F metallothionein 1F (functional) 2,10
APPBP1 amyloid beta precursor protein binding protein 1, 59 
kDa
2,35 CAMK4 calcium/calmodulin-dependent protein kinase IV 2,07
SLC5A6 solute carrier family 5 (sodium-dependent vitamin 
transporter), member 6
2,18 DCT dopachrome tautomerase (dopachrome delta-
isomerase, tyrosine-related protein 2)
2,15
CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain
2,67 EFG1 mitochondrial elongation factor G1 2,61
FYN FYN oncogene related to SRC, FGR, YES 2,25 LDB2 LIM domain binding 2 2,24
FDFT1 farnesyl-diphosphate farnesyltransferase 1 2,42 COL9A3 collagen, type IX, alpha 3 4,45
GDF11 growth differentiation factor 11 2,44 BAIAP1 BAI1-associated protein 1 2,02
FOXO1A forkhead box O1A (rhabdomyosarcoma) 2,38 ALDH1A3 aldehyde dehydrogenase 1 family, member A3 3,65
PSPC1 paraspeckle component 1 2,04 HSJ001348 cDNA for differentially expressed CO16 gene 3,79
CLCN5 chloride channel 5 (nephrolithiasis 2, X-linked, Dent 
disease)
2,10 IRAK1 interleukin-1 receptor-associated kinase 1 2,02
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 2,86
MT1G metallothionein 1G 2,98
PRKCA protein kinase C, alpha 2,27Journal of Carcinogenesis 2008, 7:1 http://www.carcinogenesis.com/content/7/1/1
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was also significant when compared to RAS mutated cell
lines (Fig. 1a). Importantly, most of the cell lines analyzed
were short term cultures which should therefore resemble
closely the parental tumor (table 1). Our results are in
accordance with previous published data demonstrating
that only a portion of regulated genes in cell lines with
BRAF or NRAS mutations are common among the differ-
ent mutations [10,11]. The different expression patterns
might be ascribed to the differential capacity to receive
input signals and to pass these on to various effectors.
In summary, BAALC may function as an additional medi-
ator of activating BRAF mutations. Future studies will
have to clarify its exact role in malignant transformation
of melanocytic lesions.
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